This discrepancy becomes particularly relevant in litigation, as defendants attempt to dismiss cases lacking specific test results despite clear clinical evidence of gastroparesis
This allows tissue recovery and reduces the buildup of irritation
Follow the dose-escalation schedule to reduce the risk of gastrointestinal adverse reactions 1 If patients do not tolerate a dose during dose escalation, consider delaying dose escalation 1 The safety and effectiveness of Wegovy tablets have not been established in pediatric patients
Cotadutide (MEDI0382) is the most extensively developed dual GLP-1/glucagon receptor agonist, showing significant improvements in glucose control, BW (likely mediated by reduced energy intake rather than increased energy expenditure), hepatic fat, and albuminuria in a small RCT on patients with T2D and overweight or obesity 45,46
Maybe, but more research is needed
Ongoing vomiting/diarrhea can cause dehydration and stress the kidneys